A year and half from its inception, Adcytherix SAS has raised a €105 million (US$122 million) series A, enabling it to take the lead antibody-drug conjugate (ADC) program into clinical development next year.
Antibody-drug conjugate specialist Tubulis GmbH has raised a hefty €308 million (US$356 million) series C to expand clinical development of TUB-040, positioning its lead program for use in additional indications and as an earlier line of therapy.
Beijing Chempion Biotechnology Co. Ltd. has synthesized antibody-drug conjugates comprising antibodies targeting folate receptor α (FOLR1; FR-α) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Ovarian cancer remains unresponsive to immune checkpoint inhibitors due to its ability to suppress cytotoxicity from immune cells that are infiltrating the tumor, where the O-glycosylation pathway may be disrupted. Precision Biologics Inc. is developing PB-vcMMAE-5, an antibody-drug conjugate composed of the monoclonal antibody PB-223, which targets tumor-specific truncated core-2 O-glycans, conjugated to microtubule inhibitor MMAE and with a drug-to-antibody ratio of 3.92.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. struck another $1 billion-plus deal, this time for a HER2-targeting antibody-drug conjugate (ADC), trastuzumab rezetecan (SHR-A1811), with Glenmark Pharmaceuticals Ltd.’s subsidiary Glenmark Specialty SA.
Simcere Zaiming Pharmaceutical Co. Ltd. has obtained IND clearance by the FDA for SIM-0609, a CDH17-targeting antibody-drug conjugate (ADC) for the treatment of advanced solid tumors. An IND was also approved in China earlier this month.
Jiangsu Hengrui Pharmaceuticals Co. Ltd. struck another $1 billion-plus deal, this time for a HER2-targeting antibody-drug conjugate (ADC), trastuzumab rezetecan (SHR-A1811), with Glenmark Pharmaceuticals Ltd.’s subsidiary Glenmark Specialty SA.
Perseus Proteomics Inc. and Ube Corp. have disclosed antibody-drug conjugates (ADCs) comprising antibodies T004b-PGAP-1 targeting human P-cadherin (CDH3) targeting covalently linked to cytotoxic drug through a linker reported to be useful for the treatment of cancer.
The oncofetal antigen 5T4 is a cell surface glycoprotein overexpressed in many solid tumors, while its expression in normal tissues is limited, making it an attractive target for cancer therapies. Its association with tumor progression and poor prognosis further supports its therapeutic potential.
RSS
